Abstract Chronic rhinosinusitis (CRS) is a very prevalent inflammatory disease. Treatments vary in different countries. In the present study, we explored the approaches of physicians in 50 countries. In this cross-sectional study, a rhinosinusitis survey (RSS) was completed by Honorary and Corresponding Members (otorhinolaryngologists) of the Italian Society of Rhinology. In 79.1 % of the 50 countries, the proportion of patients suffering from CRS was 15 %. Nasal symptoms were more intense in winter (46 % of countries), and spring and autumn (22 %). The most common symptoms were nasal obstruction (86 %), postnasal drip (82 %) and headache (52 %). The most common investigative modalities in the assessment of CRS are paranasal sinus CT, fiberoptic endoscopy, and anterior rhinoscopy. CRS patients were principally treated by otorhinolaryngologists (70 %). Medical treatments included nasal corticosteroids (90 %), nasal washes (68 %), and nasal decongestants (32 %). In 88 % of countries, more than 50 %, or ''about 50 %'', of all patients reported subjective symptom improvement after treatment. In most of the countries, surgery was required by 20-35 % of all CRS patients. During post-surgery follow-up, nasal washes (90 %), nasal corticosteroids (76 %), and systemic antibiotics (32 %) were prescribed. In 20-40 % of all patients, CRS was associated with nasal polyps. In such patients, the medical treatment options were nasal corticosteroids (90 %), systemic corticosteroids (50 %), nasal washes (46 %), and systemic antibiotics (34 %). Treatment of CRS patients varies in different countries. Paranasal sinus CT is the most common investigative modality in the assessment of CRS, and nasal corticosteroids are the first-line treatment, in the absence or presence of nasal polyps.
Introduction
Chronic rhinosinusitis (CRS) is a very prevalent inflammatory disease that substantially affects patient quality-oflife and productivity [1] [2] [3] . CRS with or without nasal polyps (CRSwNP or CRSsNP, respectively) in adults is diagnosed by the presence of two or more symptoms, one of which is either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); the other symptoms are facial pain/pressure and reduction in or loss of smell. Symptoms must persist for C12 weeks, and may be validated by telephone or consultation [3] . CRS affects 15.5 % of the total population of the United States [4] . In another study in Sao Paulo, patients were personally interviewed, and CRS was defined using the EPOS criteria. The prevalence was 5.5 % [5] .
The immunological patterns of CRSwNP and CRSsNP differ. Inflammation is rarely prominent in CRSsNP patients, although a few studies have shown that CRSsNP is characterized by type 1 inflammation. On the other hand, inflammation associated with CRSwNP has been well studied. In Western countries, CRSwNP is associated with type 2 inflammation and eosinophilia of the nasal polyps. In contrast, mixed inflammatory patterns are evident in Asian CRSwNP patients; the ratio of eosinophilic to noneosinophilic polyps is approximately 1:1 in this region. Inflammation of eosinophilic nasal polyps is principally mediated by the type 2 cytokines IL-5 and IL-13, which are produced by several types of immune cells including Th2, mast, and group 2 innate lymphoid cells (ILC2s), the levels of which are elevated in eosinophilic polyps. IL-5 is a strong inducer of eosinophilia. IL-13 activates macrophages, B cells, and epithelial cells, triggers the recruitment of eosinophils and Th2 cells, and induces IgEmediated reactions and remodeling. The epithelial cellderived cytokines, TSLP, IL-33, and IL-1, both directly and indirectly control type 2 cytokine production from cells such as eosinophilic polyps [6] .
About 25 % of CRS patients experience comorbid anxiety; both conditions independently reduce the qualityof-life [7] . Therefore, treatment including (if necessary) surgery is essential. Chester [8] reported that headache and hyposmia improved to a lesser extent than nasal obstruction after endoscopic sinus surgery (ESS) [8] . Treatment approaches vary among countries and physicians. In the present cross-sectional study, a rhinosinusitis survey (RSS) questionnaire was sent to Honorary and Corresponding Members of the Italian Society of Rhinology. Responses were received from otorhinolaryngologists in 50 countries.
Materials and methods
Answers were received from 50 countries: Angola, Albania, Algeria, Armenia, Azerbaijan, Bangladesh, Chile, Cyprus, Korea, Croatia, Denmark, Ecuador, El Salvador, The Philippines, Finland, Germany, Japan, Greece, Guatemala, India, Iran, Kazakhstan, Lebanon, Lithuania, Nepal, Macedonia, Malaysia, Malta, Mexico, Moldova, Mongolia, Pakistan, Panama, Poland, Portugal, Czech Republic, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, South Africa, Thailand, Taiwan, Turkey, United Arab Emirates, the Ukraine, and the United States.
Subjects
The Honorary and Corresponding Members of the Italian Society of Rhinology represent over 80 people from 80 different countries (website: http://www.societaitalianar inologia.it/home/index.php/chi-siamo/soci-onorari-e-corris pondenti?limitstart=0; enter via SIR and then click ''Honorary Members''. Accessed on 4 Jan 2016). Responses were received from 50 countries (Table 1) .
RSS
We prepared an RSS featuring 19 questions on rhinosinusitis (Appendix 1). Questions Q1, Q7, Q8, Q9, Q11, Q16, Q17, and Q18, allowed only one answer. The other questions invited multiple responses. The proportions of various options (percentages) were calculated for all 19 questions.
Results
Of the 88 specialists who received the RSS, 52 (59 %) responded to all of the questions, and 50 of these responses were fully analyzed (two responses lacked three or more answers). The mean respondent age was 57 years (range 42-73 years; 84 % male). In total, 20 respondents worked in hospitals, 5 were field physicians, 4 were private practitioners, and 21 worked in university settings. Responses to all of the questions were separately evaluated. Q1: What percentage of patients suffer from chronic rhinosinusitis (CRS) in your Country?
This question was answered by respondents from 48 countries. In 38 respondents (79.1 %), the percentage of patients suffering from CRS was 15 %. In nine countries (18.8 %), the figure was 25 %, and in one country, it was 50 % (Fig. 1) .
Q2: What times of the year are nasal symptoms more intense?
Nasal symptoms were more intense in spring (11/50 countries, 22 %), summer (2/50 countries, 2 %), autumn (11/50 countries, 22 %), winter (28/50 countries, 46 %), and ''always'' (13/50 countries, 26 %) (Fig. 2) .
Q3. Among the following, which are the most common symptoms reported by patients diagnosed with CRS?
The most common symptoms were nasal obstruction (86 %), postnasal drip (82 %), headache (52 %), anterior rhinorrhea and hyposmia (46 %), cough (38 %), and facial pain (32 %). Rare symptoms included fever (4 %), cacosmia, lacrimation, and photophobia (2 %). The countries of Angola, Armenia, Azerbaijan, Greece, Kazakhstan, Nepal, Malaysia, Slovakia, South Africa, and the United States stated headache as a second major symptom for their CRS patients.
Q4. Which objective investigations do you perform when assessing a patient with probable CRS?
CT of the nose and paranasal sinuses was the preferred investigative tool (82 %). Fiberoptic endoscopy (74 %) and anterior rhinoscopy (58 %) were also used. Nasal mucosal cytology, biopsy, bacteriology (14 %), and sinus transillumination (2 %) were rarely used ( Table 2) .
Q5. Which are the most frequently involved sinuses (CT evaluation)?
The ethmoid (90 %) and maxillary sinuses (70 %) were the most frequently involved. All-sinus involvement (4 %), and sphenoid and frontal sinus involvement (2 %) were rare.
Q6. What is your preferred medical treatment?
Nasal corticosteroids (90 %), nasal washes (68 %), and nasal decongestant drugs (32 %) were the preferred medical treatments. Systemic corticosteroids and local antibiotics (14 %), and systemic NSAIDs (8 %), were rarely used.
Q7. For how long do you prescribe intranasal therapy before seeing patients again?
Intranasal therapy was prescribed for 1 month (52 %) and 2 months (32 %), whereas 3 months (14 %) and more than 3 months (2 %) were rarely chosen.
Q8. How many patients report subjective symptom improvement after treatment?
More than 50 % of all of the patients (in 50 % of countries) and ''about 50 %'' of patients (in 38 % of countries) reported subjective improvements after treatment. In 12 countries, the percentage of patients reporting such improvement was about 35 %, and in 10 % of countries, subjective improvement was reported by about 20 % of patients. Nasal washes (90 %), nasal corticosteroids (76 %), and systemic antibiotics (32 %) were principally recommended. Nasal decongestant drugs (16 %), systemic corticosteroids (12 %), local antibiotics, and systemic NSAIDs (8 %) were rare treatment options.
Q11. What percentage of your CRS patients has nasal polyps?
In 44 % of countries, CRS was associated with nasal polyps in about 20 % of patients. In 34 % of countries, the figure was 40 %.
Q12. What is your medical treatment of choice for a patient with nasal polyposis?
The medical treatment options were nasal corticosteroids (90 %), systemic corticosteroids (50 %), nasal washes (46 %), and systemic antibiotics (34 %). Rare treatment options included nasal decongestant drugs (6 %), systemic NSAIDs (4 %), and local antibiotics (2 %).
Q13. Which device do you prefer when administering drugs during post-operative follow-up of a patient with CRS and polyps?
Nasal sprays (78 %) and nasal douches (48 %) were favored during post-operative follow-up. Rare options included nasal drops (14 %), aerosols (6 %), and systemic antibiotics (4 %).
Q14. What is your medical treatment of choice during post-operative follow-up of a patient with CRS and polyps?
Nasal corticosteroids (94 %), nasal washes (74 %), and systemic antibiotics (26 %) were the medical treatment options chosen.
Q15. How often do you schedule follow-up visits? Three months (62 %) and every 6 months (22 %) were preferred.
Q16. What is the recurrence rate 3 years after surgery in your patients with nasal polyposis?
The recurrence rate was about 25 % in 46 % of countries, and about 10 % in 40 % of countries 3 years after surgery.
Q17. What is your medical treatment of choice for a CRS patient with allergic rhinitis?
Traditional medical therapy was the preferred option in all of the countries (100 %). Neither homeopathic treatment nor herbal medicine was recommended.
Q18. When do you treat allergic patients? Treatment was delivered all year round (40 %), and before and during the period of acute illness (38 %).
Q19. In your country, which is the first practitioner whom a CRS patients sees?
The first practitioner was an otorhinolaryngologist (70 %) or general practitioner (58 %).
Discussion
CRS is a surprisingly common, poorly defined, and notoriously difficult to treat disease. The pathophysiology is complex, and often but not always, features infection of the nasal or paranasal sinuses. Anatomical variation predisposing sinuses to obstruction may play a role in disease, but are not usually the sole causes of chronic conditions. Other possible causative factors include allergic or nonallergic inflammation, mucociliary dysfunction, aspirin intolerance (Samter's triad), immunodeficiency, and cystic fibrosis [8] .
Family studies have shown that CRS has a heritability of 13-53 % [9] [10] [11] .
CRS affects approximately 5-15 % of the general populations of Europe and the United States. The prevalence of physician-diagnosed CRS was 2-4 % [3] . We found that, in 79.1 % of countries, 15 % of patients suffered from CRS. Nasal symptoms were more intense in winter (46 %), and spring and autumn (22 %). Lima et al. [12] reported that, of asymptomatic CRS patients, peak numbers were detected in the autumn and winter. CRS is diagnosed throughout the year in countries with extensive coastlines (the Philippines, Korea, Croatia, Malta, and South Africa). Philippines does not have seasons. In this country, it is hot and sometimes wet all year round. Korea has four seasons, with a wet monsoon/summer in the middle of the year, and a cold winter from November to March [13]. Croatia's coast and islands, from Istria and Kvarner in the north through to Dalmatia in the south are governed by a Mediterranean climate, although it is usually several degrees cooler in the northern Adriatic than in the south [14] . Malta has a subtropical-Mediterranean climate with very mild winters and warm to hot summers. Rain occurs mainly in winter, with summer being generally dry [15] . South Africa has a wider variety of climates than most other countries in sub-Saharan Africa, and it has lower average temperatures than other countries within this range of latitude, like Australia, because much of the interior of South Africa is at higher elevation [16] .
McNally et al. [17] found that the most common CRS symptoms were nasal congestion (73 %), postnasal drip (69 %), purulent rhinorrhea (65 %), headache (48 %), cough (47 %), facial pressure (42 %), anosmia or hyposmia (39 %), wheezing (34 %), hypogeusia (29 %), and throat clearing (29 %). We found that the most common symptoms were nasal obstruction (86 %), postnasal drip (82 %), headache (52 %), and anterior rhinorrhea and hyposmia (46 %). Lobid et al. [18] reported that the most common symptom was nasal obstruction. Our respondents considered that headache and facial pain were both very common (and significant) symptoms of CRS patients (53.0 % and 30.6 %, respectively). However, headache is not the only symptom; history-taking and a clinical examination should be performed to reduce the need for CT or an X-ray if headache alone is present.
In patients with nasal polyps, any or all of hypoxia, hypercapnia, snoring, sleep disorders, and hypertension may develop [18] . Mucha and Baroody [19] considered that CRS diagnosis should include the evaluation of symptomatology, physical and endoscopic findings, CT scans, and culture results. Symptoms and CT scan scores correlated poorly, but middle meatal culture results correlated well with ethmoid sinus culture data from CRS patients. It was concluded that clinical symptoms are important when diagnosing CRS, and should be supported by objective findings yielded by nasal endoscopy, and if necessary, CT.
For assessment of CRS, our experts generally used more than one tool which were mainly paranasal sinus CT (82 %), fiberoptic endoscopy (74 %), and anterior rhinoscopy (58 %). In Angola, anterior rhinoscopy was performed alone; Croatia, Nepal, Mexico, Romania, Slovakia, and Spain, fiberoptic endoscopy was performed alone; El Salvador, Germany, Guatemala, India, Iran, and Korea, CT of the nose and paranasal sinuses was performed alone. In the other countries, mostly used tools are written above (paranasal sinus CT, fiberoptic endoscopy, and anterior rhinoscopy). There are some differences for approaches to CRS between the countries, however it may be said that most of the countries used more than one tool to assess CRS. The ethmoid (90 %) and maxillary sinuses (70 %) were the most frequently involved. CRS patients were principally referred to otorhinolaryngologists (70 %).
CRS treatments seek to reduce mucosal inflammation, control infection, and restore mucociliary clearance within the sinuses. The principal aim of this article was to outline a rational approach towards the treatment of chronic sinus disease using all of the currently available diagnostic and therapeutic techniques. Emphasis should be placed on the management, therapeutic response, and objective evaluation of therapeutic efficacy [20] . Vining [21] reported that medical therapies for CRS include corticosteroids, antibiotics, antifungal agents, antihistamines, leukotriene modifiers, nasal decongestants, mucolytics, and nasal irrigations. The selection of appropriate therapy is based on endoscopic evaluation, sinus culture, and the symptoms requiring treatment [21] . To treat CRS, intranasal corticosteroids [22] , systemic corticosteroids [23] , systemic antibiotics countering acute exacerbations [24] [25] [26] , topical antibiotics [27] , intranasal and systemic antifungals [28] , antileukotrienes [29, 30] , and intranasal saline [31] have been reported in the literature.
We found that, in 90 % of countries, nasal steroids were recommended. Nasal washes (68 % of countries) and nasal decongestant drugs (32 %) were also popular. There are different treatment combinations for CRS. For example, nasal wash, nasal decongestant drugs, nasal corticosteroids and systemic antibiotics were recommended by the experts of Azerbaijan, Bangladesh, Chile, Cyprus and Turkey. Nasal wash, nasal corticosteroids, and systemic antibiotics were recommended by Korea, Croatia, United Arab Emirates, Ecuador, Japan, Greece, Slovenia, and Taiwan. Nasal corticosteroids and systemic antibiotics were recommended by El Salvador, Lithuania, Macedonia, Malaysia, and Malta. Nasal wash and nasal corticosteroids were recommended by Czech Republic, Russia, Serbia, and USA. Intranasal therapy was continued for 1 (52 % of countries) or 2 months (32 %).
Notably, the countries with the largest proportions of patients who did not respond to medical treatment were those bordering the Baltic Sea (Denmark, Finland, and Poland). Settipane [32] reported that patients may significantly benefit from medical treatment prior to surgery, to minimize mucosal edema, polypoid thickening, and any overriding infection. Such treatment may facilitate better anatomical visualization by the surgeon, minimize postoperative infection, and possibly promote faster post-operative recovery of mucociliary function. Patients were routinely seen 2 weeks after surgery, at which time rhinoscopy was performed and the need for antibiotic and/or anti-inflammatory treatment was reassessed [32] . We found that, in 88 % of countries, more than 50 % or ''about 50 %'' of patients reported subjective improvements in symptoms after treatment.
ESS is safe and effective when used to manage CRS patients without nasal polyps when medical treatment fails. ESS is more effective in the management of nasal obstruction and facial pain than a postnasal drip or hyposmia, and is associated with significant improvements in both generic and disease-specific quality-of-life outcomes [33] . In most countries, 20-35 % of CRS patients required surgery. Nasal washes (90 %), nasal corticosteroids (76 %), and systemic antibiotics (32 %) were prescribed during post-surgery follow-up. The European position paper on rhinosinusitis and nasal polyps [33] , discussing the post-operative treatment of CRSsNP patients, recommended topical steroids, saline irrigation, saline irrigation with xylitol, short-term (\4 weeks) oral antibiotic therapy during exacerbations, and long-term (C12 weeks) oral antibiotic therapy (especially if IgE levels were not elevated).
In terms of post-surgery follow-up, the treatments of choice were nasal washes in 45/50 countries (90 %) and Nasal polyposis is a subtype of CRS; the term ''polyp'' refers to an outgrowth of tissue into the nasal cavity. The most common site of origin of such polyps is the anterior ethmoid region. Nasal polyps cause nasal obstruction, hyposmia, recurrent infections, and impaired quality-oflife. Of all patients with nasal polyps, 20-90 % had asthma [35] . Approximately 20 % of all patients with chronic sinusitis had nasal polyposis [32] . We found that CRS was associated with nasal polyps in 20-40 % of all patients.
Topical corticosteroids are beneficial for the treatment of CRSwNP. Any adverse effect is minor; the benefits outweigh the risks. Corticosteroids improve symptoms, reduce polyp size, and prevent polyp recurrence after surgery. Patients subjected to sinus surgery may exhibit better responses to topical corticosteroids, but further research is required [32] . Intranasal corticosteroids, short courses of oral steroids, and antileukotrienes were recommended for CRSwNP patients. In addition, because Staphylococcus aureus frequently colonizes the nasal mucosa of such patients, doxycycline may be prescribed [35, 36] We found that, in CRSwNP patients, the medical treatment options were nasal corticosteroids (90 % of countries), systemic corticosteroids (50 %), nasal washes (46 %), and systemic antibiotics (34 %). During post-operative follow-up, nasal sprays (78 % of countries) and nasal douches (48 %) were used as delivery devices; and nasal corticosteroids (94 %) and nasal washes (74 %) as medical treatments. Follow-up visits were scheduled every 3 months. Recurrence rates were 10-25 % 3 years after surgery. The European position paper on rhinosinusitis and nasal polyps [33] recommend that the post-operative treatment of CRSwNP patients may include topical steroids, oral steroids, short-term (\4 weeks) oral antibiotic therapy (which had only a small effect), anti-IL-5 therapy, and longterm (C12 weeks) oral antibiotic therapy (but only when IgE levels were not increased).
After ESS to treat nasal polyps, symptomatic improvements were evident in up to 98 % of CRSwNP patients, with low frequencies of major complications (0-1.5 %). Minor complications developed in 1.1-20.8 % of patients [37] . The potentially most serious complications were cerebrospinal fluid leakage, injury to the internal carotid artery, dural exposure, meningitis, bleeding requiring transfusion, periorbital/orbital fat exposure, and orbital penetration. Symptomatic improvements after ESS were reported in 78-88 % of patients compared to 43-84 % after comparative procedures. In one case series, symptomatic improvements were noted in 40-98 % of patients (median, 88 %) [37] .
Rimmer et al. [38] searched the Cochrane database and compared the effectiveness of endonasal/endoscopic surgery to that of medical treatment in CRS patients with nasal polyps. Two studies (one comparing ESS plus topical steroid with antibiotics plus high-dose topical steroid; the other ESS with systemic steroid) failed to find any between-treatment difference in generic health-related quality-of-life scores. The quality of the evidence was low or very low. Two studies considered endoscopic scores. One study (ESS versus systemic steroid) found a large significant ES in the surgical group, with a mean difference (MD) score of -1.5 (95 % CI, -1.78 to -1.22; n = 95) on a scale of 0-3 (0 = no polyposis, 3 = severe polyposis). In the other study (ESS plus topical steroid compared to antibiotics plus high-dose topical steroid), no betweengroup difference was noted (MD, 2.3 %; 95 % CI, -17.4 to 12.8 %; n = 34). No study reported a recurrence rate. We found that patients with chronic sinusitis and allergic rhinitis were treated with traditional medical therapies worldwide. In allergic patients, treatment was recommended all year round (40 %), or before and during the period of acute illness (38 %).
Rhinosinusitis was diagnosed earlier by a wide variety of practitioners, including allergologists, otorhinolaryngologists, pulmonologists, primary care physicians, pediatricians, and many others [3] . However, we found that CRS patients were usually seen by otorhinolaryngologists and general practitioners. It was interesting to note that 10.2 % of all respondents indicated that allergologists were the first to see a patient with CRS. In the Middle East (Lebanon, Armenia), both allergologists and otorhinolaryngologists play such roles. This cross-sectional international study on CRSwNP and CRSsNP examined the approaches of otorhinolaryngologists worldwide, and explored CRS diagnosis, treatment, and follow-up (medical and surgical).
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